<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447407</url>
  </required_header>
  <id_info>
    <org_study_id>NDV3-002</org_study_id>
    <nct_id>NCT01447407</nct_id>
  </id_info>
  <brief_title>Effect of Adjuvant &amp; Route of Administration on Safety &amp; Immunogenicity of NDV-3 Vaccine</brief_title>
  <official_title>Phase 1b Study to Evaluate the Safety and Immunogenicity of NDV-3 Formulated With or Without Alum (AlOH) and Administered Either Intramuscular (IM) or Intradermally (ID) to Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovaDigm Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>NovaDigm Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This partially-blind, placebo controlled study is a Phase 1b study using an investigational
      vaccine, NDV-3, directed against Staphylococcus aureus and Candida sp. This study will
      compare NDV-3 administered with or without alum delivered intramuscularly (IM) at one dose
      level. It will also evaluate a lower dose of NDV-3 without alum delivered intradermally (ID)
      compared to placebo delivered ID.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preclinical studies in mice have established that several members of the Als family of
      proteins induce a protective immune response in mice and allow high survival rates following
      challenge with highly virulent doses of either Candida or S. aureus. Als3 (the antigen in the
      NDV-3 investigational vaccine) is the most effective member of the Als protein family in
      protecting mice from challenge with either Candida or S. aureus. The first Phase 1 study
      enrolled 40 healthy subjects that received placebo (N=10), 1 dose (N=30) or 2 doses (N=19) of
      the NDV-3 vaccine administered intramuscularly (IM). The vaccine was well tolerated and
      highly immunogenic. This study will evaluate the safety, tolerability and immunogenicity of
      one dose of NDV-3 vaccine formulated with and without alum given IM and also a lower dose
      without alum given intradermally (ID). Subjects will have follow-up visits to assess the
      safety tolerability and immune responses at selected time points up to 90 days
      post-vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>Up to 90 days post-vaccination</time_frame>
    <description>The primary objective of this study is to assess the safety of a single dose of NDV-3 vaccine, administered either IM with or without alum adjuvant at one dose level or ID at a lower dose level, compared to placebo. Clinical evaluations will be assessed on each subject at selected time points up to 90 days post-vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Serum Anti-Als3 IgG</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 28, Day 90/Exit</time_frame>
    <description>A secondary objective is to compare the serum IgG immune response between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. Serum IgG will be evaluated by ELISA on serial-diluted samples, resulting in titer values of reciprocal dilution at which the ELISA readout is three times greater than the assay background value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Serum Anti-Als3 IgA1</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 28, Day 90/Exit</time_frame>
    <description>A secondary objective is to compare the serum IgA1 immune response between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. Serum IgA1 will be evaluated by ELISA on serial-diluted samples, resulting in titer values of reciprocal dilution at which the ELISA readout is three times greater than the assay background value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Cervicovaginal Wash Anti-Als3 IgG</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 28, Day 90/Exit</time_frame>
    <description>A secondary objective is to compare the cervicovaginal wash IgG immune response between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. Cervicovaginal wash IgG will be evaluated by ELISA on serial-diluted samples, resulting in titer values of reciprocal dilution at which the ELISA readout is three times greater than the assay background value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Cervicovaginal Wash Anti-Als3 IgA1</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 28, Day 90/Exit</time_frame>
    <description>A secondary objective is to compare the cervicovaginal wash IgA1 immune response between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. Cervicovaginal wash IgA1 will be evaluated by ELISA on serial-diluted samples, resulting in titer values of reciprocal dilution at which the ELISA readout is three times greater than the assay background value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Number of Participants Positive for Peripheral Blood Mononuclear Cells (PBMCs) Producing Als3-specific Interferon-gamma (IFN-g)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 28, Day 90/Exit</time_frame>
    <description>A secondary objective is to compare the cellular immune response for Als3-specific production of IFN-g from PBMCs between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. The IFN-g cellular immune responses will be evaluated by ELISpot using approximately 200,000 PBMCs per well. A positive response was defined as a sample with greater than 20 spot forming units per 10^6 PBMCs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Number of Participants Positive for Peripheral Blood Mononuclear Cells (PBMCs) Producing Als3-specific Interleukin-17A (IL-17A)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 28, Day 90/Exit</time_frame>
    <description>A secondary objective is to compare the cellular immune response for Als3-specific production of IL-17A from PBMCs between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. The IL-17A cellular immune responses will be evaluated by ELISpot using approximately 200,000 PBMCs per well. A positive response was defined as a sample with greater than 20 spot forming units per 10^6 PBMCs.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Staphylococcal Infections</condition>
  <condition>Yeast Infections</condition>
  <condition>Candidiasis</condition>
  <arm_group>
    <arm_group_label>NDV-3 vaccine with alum IM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 ug Als3 and 0.5 mg Al as alum in PBS per dose, one dose administered IM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NDV-3 vaccine without alum IM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 ug Als3 in PBS per dose, one dose administered IM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo IM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.5 mg Al as alum in PBS per dose, one dose administered IM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NDV-3 vaccine without alum ID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 ug Als3 in PBS per dose, one dose administered ID</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NDV-3 vaccine with alum IM</intervention_name>
    <description>One dose administered IM</description>
    <arm_group_label>NDV-3 vaccine with alum IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NDV-3 vaccine without alum IM</intervention_name>
    <description>One dose administered IM</description>
    <arm_group_label>NDV-3 vaccine without alum IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo with alum IM</intervention_name>
    <description>One dose administered ID</description>
    <arm_group_label>Placebo IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NDV-3 vaccine without alum ID</intervention_name>
    <description>One dose administered ID</description>
    <arm_group_label>NDV-3 vaccine without alum ID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed of the nature of the study and have agreed to and are able to read, review,
             and sign the informed consent document prior to screening. The informed consent
             document will be written in English, therefore the volunteer must have the ability to
             read and communicate in English.

          2. Completed the screening process (as described in this protocol) within 28 days prior
             to dosing.

          3. Healthy male and female volunteers 18-50 years of age, inclusive, at the time of
             dosing.

          4. No clinically significant deviation from normal as judged by the investigator(s) in
             the medical history, physical examination (including but may not be limited to an
             evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous
             systems), vital sign assessments, 12-lead electrocardiogram (ECG), clinical laboratory
             assessments, and by general observations.

          5. Female volunteers must be one of the following:

               -  of childbearing potential and practicing an acceptable method of birth control as
                  judged by the Investigator(s)

               -  naturally postmenopausal (no menses) for at least 1 year and has a documented FSH
                  level ≥ 40 mIU/mL

               -  surgically postmenopausal (bilateral oophorectomy or hysterectomy)

               -  sterile (surgically [bilateral tubal ligation] or the Essure® Procedure) Female
                  volunteers that are surgically sterile or surgically postmenopausal must provide
                  documentation of the bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy prior to dosing or the volunteer must agree to use a medically
                  acceptable method of birth control. The Essure® Procedure must have been inserted
                  at least 3 months prior with documentation of the Essure® confirmation test prior
                  to Period I dosing. If the procedure was inserted less than 3 months prior to
                  Period I dosing or proper documentation of the confirmation test is not provided,
                  the volunteer must agree to use an additional medically acceptable method of
                  birth control.

        Exclusion Criteria:

          1. Reports receiving any investigational drug, investigational vaccine, or
             investigational device within 30 days prior to dosing.

          2. Reports any presence or history of a clinically significant disorder involving the
             cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic,
             endocrine, or neurologic system(s) or psychiatric disease as determined by the
             Investigator(s).

          3. Clinical laboratory test values outside the accepted range.

          4. When confirmed upon additional testing, demonstrates a reactive screen for hepatitis B
             surface antigen, hepatitis C antibody, or HIV antibody.

          5. Demonstrates a positive drug screen for non-prescription drugs.

          6. Reports a clinically significant illness during the 28 days prior to dosing (as
             determined by the Investigator[s]).

          7. Reports a history of allergic response(s) to nickel or anaphylaxis (or other serious
             reactions) to aluminum.

          8. Reports receiving any live attenuated vaccine including FluMist® within 6 weeks prior
             to dosing or any licensed inactivated vaccine within 3 weeks prior to dosing.

          9. Reports the use of any immunosuppressive drugs, including systemic corticosteroids,
             within 4 weeks prior to dosing.

         10. Reports the use of any medications or treatments that may alter immune responses to
             the study vaccine within 3 weeks prior to dosing (eg, cyclosporine, tacrolimus,
             cytotoxic drugs, immune globulin, Bacillus Calmette-Guerin [BCG], monoclonal
             antibodies, radiation therapy).

         11. Reports a history of clinically significant allergies including food or drug allergies
             or anaphylaxis (or other serious reactions) to vaccines.

         12. Reports a history of drug or alcohol addiction or abuse within the past year.

         13. Reports receiving any blood products within 3 months prior to dosing and throughout
             the study.

         14. Reports donating blood within 28 days prior to dosing. All subjects will be advised
             not to donate blood for four weeks after completing the study.

         15. Reports donating plasma (e.g. plasmapheresis) within 14 days prior to dosing. All
             subjects will be advised not to donate plasma for four weeks after completing the
             study.

         16. Demonstrates, in the opinion of study staff, veins unsuitable for repeated
             venipuncture (e.g. veins difficult to locate, access, or puncture; veins with a
             tendency to rupture during or after puncture).

         17. Pregnant, lactating, breastfeeding, or intends to become pregnant over the course of
             the study.

         18. Demonstrates a positive pregnancy screen.

         19. Reports smoking or using tobacco products or is currently using nicotine products
             (patches, gums, etc). Thirty (30) days abstinence prior to dosing is required.

         20. Any other medical and/or social (e.g. uncooperative or non-compliant) reason which, in
             the opinion of the investigator(s), would prevent participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cetero Research Clinical Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schmidt CS, White CJ, Ibrahim AS, Filler SG, Fu Y, Yeaman MR, Edwards JE Jr, Hennessey JP Jr. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine. 2012 Dec 14;30(52):7594-600. doi: 10.1016/j.vaccine.2012.10.038. Epub 2012 Oct 22.</citation>
    <PMID>23099329</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 3, 2011</study_first_submitted>
  <study_first_submitted_qc>October 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2011</study_first_posted>
  <results_first_submitted>January 28, 2020</results_first_submitted>
  <results_first_submitted_qc>February 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 4, 2020</results_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Staphylococcal infections</keyword>
  <keyword>Yeast infections</keyword>
  <keyword>Candidiasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Four subjects withdrew before completing Day 28 and were replaced. One subject withdrew before the last visit. While this subject is not considered to have completed the study, data from this subject are included in the immunogenicity and culture results.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NDV-3 Vaccine With Alum</title>
          <description>NDV-3 (300 ug Als3) vaccine with alum administered IM: One dose administered IM</description>
        </group>
        <group group_id="P2">
          <title>NDV-3 Vaccine Without Alum</title>
          <description>NDV-3 (300 ug Als3) vaccine without alum administered IM: One dose administered IM</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo administered ID: One dose saline placebo administered ID</description>
        </group>
        <group group_id="P4">
          <title>NDV-3 Vaccine ID</title>
          <description>NDV-3 (30 ug Als3) vaccine without alum administered ID: One dose administered ID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NDV-3 Vaccine With Alum</title>
          <description>NDV-3 (300 ug Als3) vaccine with alum administered IM: One dose administered IM</description>
        </group>
        <group group_id="B2">
          <title>NDV-3 Vaccine Without Alum</title>
          <description>NDV-3 (300 ug Als3) vaccine without alum administered IM: One dose administered IM</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo administered ID: One dose saline placebo administered ID</description>
        </group>
        <group group_id="B4">
          <title>NDV-3 Vaccine ID</title>
          <description>NDV-3 (30 ug Als3) vaccine without alum administered ID: One dose administered ID</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="42"/>
            <count group_id="B5" value="164"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.8" lower_limit="18" upper_limit="47"/>
                    <measurement group_id="B2" value="30.1" lower_limit="18" upper_limit="49"/>
                    <measurement group_id="B3" value="32.3" lower_limit="19" upper_limit="50"/>
                    <measurement group_id="B4" value="31.0" lower_limit="18" upper_limit="50"/>
                    <measurement group_id="B5" value="31.3" lower_limit="18" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events</title>
        <description>The primary objective of this study is to assess the safety of a single dose of NDV-3 vaccine, administered either IM with or without alum adjuvant at one dose level or ID at a lower dose level, compared to placebo. Clinical evaluations will be assessed on each subject at selected time points up to 90 days post-vaccination.</description>
        <time_frame>Up to 90 days post-vaccination</time_frame>
        <population>All subjects completing study. Additionally, a subject in Group 4 withdrew from the study before the very last visit, so while this subject is not considered to have completed the study, immunogenicity and culture data for this subject were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NDV-3 Vaccine With Alum</title>
            <description>NDV-3 (300 ug Als3) vaccine with alum administered IM: One dose administered IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3 Vaccine Without Alum</title>
            <description>NDV-3 (300 ug Als3) vaccine without alum administered IM: One dose administered IM</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered ID: One dose saline placebo administered ID</description>
          </group>
          <group group_id="O4">
            <title>NDV-3 Vaccine ID</title>
            <description>NDV-3 (30 ug Als3) vaccine without alum administered ID: One dose administered ID</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events</title>
          <description>The primary objective of this study is to assess the safety of a single dose of NDV-3 vaccine, administered either IM with or without alum adjuvant at one dose level or ID at a lower dose level, compared to placebo. Clinical evaluations will be assessed on each subject at selected time points up to 90 days post-vaccination.</description>
          <population>All subjects completing study. Additionally, a subject in Group 4 withdrew from the study before the very last visit, so while this subject is not considered to have completed the study, immunogenicity and culture data for this subject were included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=1 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 severe drug-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DIscontinued for &gt;=1 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity - Serum Anti-Als3 IgG</title>
        <description>A secondary objective is to compare the serum IgG immune response between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. Serum IgG will be evaluated by ELISA on serial-diluted samples, resulting in titer values of reciprocal dilution at which the ELISA readout is three times greater than the assay background value.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 28, Day 90/Exit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NDV-3 Vaccine With Alum</title>
            <description>NDV-3 (300 ug Als3) vaccine with alum administered IM: One dose administered IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3 Vaccine Without Alum</title>
            <description>NDV-3 (300 ug Als3) vaccine without alum administered IM: One dose administered IM</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered ID: One dose saline placebo administered ID</description>
          </group>
          <group group_id="O4">
            <title>NDV-3 Vaccine ID</title>
            <description>NDV-3 (30 ug Als3) vaccine without alum administered ID: One dose administered ID</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity - Serum Anti-Als3 IgG</title>
          <description>A secondary objective is to compare the serum IgG immune response between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. Serum IgG will be evaluated by ELISA on serial-diluted samples, resulting in titer values of reciprocal dilution at which the ELISA readout is three times greater than the assay background value.</description>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372" spread="3.12"/>
                    <measurement group_id="O2" value="320" spread="3.07"/>
                    <measurement group_id="O3" value="363" spread="2.93"/>
                    <measurement group_id="O4" value="375" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4447" spread="6.31"/>
                    <measurement group_id="O2" value="3070" spread="6.71"/>
                    <measurement group_id="O3" value="365" spread="2.81"/>
                    <measurement group_id="O4" value="874" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44675" spread="3.04"/>
                    <measurement group_id="O2" value="22675" spread="6.58"/>
                    <measurement group_id="O3" value="370" spread="2.89"/>
                    <measurement group_id="O4" value="5153" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38898" spread="2.83"/>
                    <measurement group_id="O2" value="19220" spread="6.00"/>
                    <measurement group_id="O3" value="377" spread="2.93"/>
                    <measurement group_id="O4" value="4513" spread="6.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90/Exit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20853" spread="3.24"/>
                    <measurement group_id="O2" value="11771" spread="5.93"/>
                    <measurement group_id="O3" value="347" spread="2.71"/>
                    <measurement group_id="O4" value="3282" spread="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity - Serum Anti-Als3 IgA1</title>
        <description>A secondary objective is to compare the serum IgA1 immune response between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. Serum IgA1 will be evaluated by ELISA on serial-diluted samples, resulting in titer values of reciprocal dilution at which the ELISA readout is three times greater than the assay background value.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 28, Day 90/Exit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NDV-3 Vaccine With Alum</title>
            <description>NDV-3 (300 ug Als3) vaccine with alum administered IM: One dose administered IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3 Vaccine Without Alum</title>
            <description>NDV-3 (300 ug Als3) vaccine without alum administered IM: One dose administered IM</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered ID: One dose saline placebo administered ID</description>
          </group>
          <group group_id="O4">
            <title>NDV-3 Vaccine ID</title>
            <description>NDV-3 (30 ug Als3) vaccine without alum administered ID: One dose administered ID</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity - Serum Anti-Als3 IgA1</title>
          <description>A secondary objective is to compare the serum IgA1 immune response between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. Serum IgA1 will be evaluated by ELISA on serial-diluted samples, resulting in titer values of reciprocal dilution at which the ELISA readout is three times greater than the assay background value.</description>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="573" spread="4.07"/>
                    <measurement group_id="O2" value="480" spread="3.44"/>
                    <measurement group_id="O3" value="418" spread="3.72"/>
                    <measurement group_id="O4" value="550" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7643" spread="6.61"/>
                    <measurement group_id="O2" value="5497" spread="7.01"/>
                    <measurement group_id="O3" value="431" spread="3.69"/>
                    <measurement group_id="O4" value="1640" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69616" spread="3.1"/>
                    <measurement group_id="O2" value="34946" spread="6.77"/>
                    <measurement group_id="O3" value="429" spread="3.93"/>
                    <measurement group_id="O4" value="9356" spread="6014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43790" spread="2.59"/>
                    <measurement group_id="O2" value="19999" spread="5.36"/>
                    <measurement group_id="O3" value="412" spread="3.86"/>
                    <measurement group_id="O4" value="7400" spread="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90/Exit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20656" spread="2.51"/>
                    <measurement group_id="O2" value="10698" spread="4.61"/>
                    <measurement group_id="O3" value="404" spread="3.78"/>
                    <measurement group_id="O4" value="3641" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity - Cervicovaginal Wash Anti-Als3 IgG</title>
        <description>A secondary objective is to compare the cervicovaginal wash IgG immune response between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. Cervicovaginal wash IgG will be evaluated by ELISA on serial-diluted samples, resulting in titer values of reciprocal dilution at which the ELISA readout is three times greater than the assay background value.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 28, Day 90/Exit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NDV-3 Vaccine With Alum</title>
            <description>NDV-3 (300 ug Als3) vaccine with alum administered IM: One dose administered IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3 Vaccine Without Alum</title>
            <description>NDV-3 (300 ug Als3) vaccine without alum administered IM: One dose administered IM</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered ID: One dose saline placebo administered ID</description>
          </group>
          <group group_id="O4">
            <title>NDV-3 Vaccine ID</title>
            <description>NDV-3 (30 ug Als3) vaccine without alum administered ID: One dose administered ID</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity - Cervicovaginal Wash Anti-Als3 IgG</title>
          <description>A secondary objective is to compare the cervicovaginal wash IgG immune response between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. Cervicovaginal wash IgG will be evaluated by ELISA on serial-diluted samples, resulting in titer values of reciprocal dilution at which the ELISA readout is three times greater than the assay background value.</description>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="1.5"/>
                    <measurement group_id="O2" value="2" spread="1.55"/>
                    <measurement group_id="O3" value="3" spread="2.12"/>
                    <measurement group_id="O4" value="3" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="3.98"/>
                    <measurement group_id="O2" value="6" spread="5.84"/>
                    <measurement group_id="O3" value="2" spread="1.61"/>
                    <measurement group_id="O4" value="3" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" spread="7.12"/>
                    <measurement group_id="O2" value="26" spread="7.50"/>
                    <measurement group_id="O3" value="3" spread="1.99"/>
                    <measurement group_id="O4" value="8" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" spread="5.85"/>
                    <measurement group_id="O2" value="26" spread="7.09"/>
                    <measurement group_id="O3" value="3" spread="2.20"/>
                    <measurement group_id="O4" value="8" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90/Exit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="4.93"/>
                    <measurement group_id="O2" value="13" spread="4.65"/>
                    <measurement group_id="O3" value="3" spread="2.11"/>
                    <measurement group_id="O4" value="6" spread="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity - Cervicovaginal Wash Anti-Als3 IgA1</title>
        <description>A secondary objective is to compare the cervicovaginal wash IgA1 immune response between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. Cervicovaginal wash IgA1 will be evaluated by ELISA on serial-diluted samples, resulting in titer values of reciprocal dilution at which the ELISA readout is three times greater than the assay background value.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 28, Day 90/Exit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NDV-3 Vaccine With Alum</title>
            <description>NDV-3 (300 ug Als3) vaccine with alum administered IM: One dose administered IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3 Vaccine Without Alum</title>
            <description>NDV-3 (300 ug Als3) vaccine without alum administered IM: One dose administered IM</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered ID: One dose saline placebo administered ID</description>
          </group>
          <group group_id="O4">
            <title>NDV-3 Vaccine ID</title>
            <description>NDV-3 (30 ug Als3) vaccine without alum administered ID: One dose administered ID</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity - Cervicovaginal Wash Anti-Als3 IgA1</title>
          <description>A secondary objective is to compare the cervicovaginal wash IgA1 immune response between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. Cervicovaginal wash IgA1 will be evaluated by ELISA on serial-diluted samples, resulting in titer values of reciprocal dilution at which the ELISA readout is three times greater than the assay background value.</description>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="2.03"/>
                    <measurement group_id="O2" value="3" spread="2.08"/>
                    <measurement group_id="O3" value="3" spread="2.24"/>
                    <measurement group_id="O4" value="3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="2.87"/>
                    <measurement group_id="O2" value="7" spread="6.64"/>
                    <measurement group_id="O3" value="3" spread="1.45"/>
                    <measurement group_id="O4" value="4" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="4.50"/>
                    <measurement group_id="O2" value="29" spread="6.48"/>
                    <measurement group_id="O3" value="3" spread="1.64"/>
                    <measurement group_id="O4" value="12" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="3.82"/>
                    <measurement group_id="O2" value="25" spread="6.72"/>
                    <measurement group_id="O3" value="3" spread="2.40"/>
                    <measurement group_id="O4" value="8" spread="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90/Exit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="3.18"/>
                    <measurement group_id="O2" value="8" spread="3.27"/>
                    <measurement group_id="O3" value="3" spread="1.98"/>
                    <measurement group_id="O4" value="5" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity - Number of Participants Positive for Peripheral Blood Mononuclear Cells (PBMCs) Producing Als3-specific Interferon-gamma (IFN-g)</title>
        <description>A secondary objective is to compare the cellular immune response for Als3-specific production of IFN-g from PBMCs between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. The IFN-g cellular immune responses will be evaluated by ELISpot using approximately 200,000 PBMCs per well. A positive response was defined as a sample with greater than 20 spot forming units per 10^6 PBMCs.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 28, Day 90/Exit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NDV-3 Vaccine With Alum</title>
            <description>NDV-3 (300 ug Als3) vaccine with alum administered IM: One dose administered IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3 Vaccine Without Alum</title>
            <description>NDV-3 (300 ug Als3) vaccine without alum administered IM: One dose administered IM</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered ID: One dose saline placebo administered ID</description>
          </group>
          <group group_id="O4">
            <title>NDV-3 Vaccine ID</title>
            <description>NDV-3 (30 ug Als3) vaccine without alum administered ID: One dose administered ID</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity - Number of Participants Positive for Peripheral Blood Mononuclear Cells (PBMCs) Producing Als3-specific Interferon-gamma (IFN-g)</title>
          <description>A secondary objective is to compare the cellular immune response for Als3-specific production of IFN-g from PBMCs between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. The IFN-g cellular immune responses will be evaluated by ELISpot using approximately 200,000 PBMCs per well. A positive response was defined as a sample with greater than 20 spot forming units per 10^6 PBMCs.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90/Exit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity - Number of Participants Positive for Peripheral Blood Mononuclear Cells (PBMCs) Producing Als3-specific Interleukin-17A (IL-17A)</title>
        <description>A secondary objective is to compare the cellular immune response for Als3-specific production of IL-17A from PBMCs between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. The IL-17A cellular immune responses will be evaluated by ELISpot using approximately 200,000 PBMCs per well. A positive response was defined as a sample with greater than 20 spot forming units per 10^6 PBMCs.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 28, Day 90/Exit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NDV-3 Vaccine With Alum</title>
            <description>NDV-3 (300 ug Als3) vaccine with alum administered IM: One dose administered IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3 Vaccine Without Alum</title>
            <description>NDV-3 (300 ug Als3) vaccine without alum administered IM: One dose administered IM</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered ID: One dose saline placebo administered ID</description>
          </group>
          <group group_id="O4">
            <title>NDV-3 Vaccine ID</title>
            <description>NDV-3 (30 ug Als3) vaccine without alum administered ID: One dose administered ID</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity - Number of Participants Positive for Peripheral Blood Mononuclear Cells (PBMCs) Producing Als3-specific Interleukin-17A (IL-17A)</title>
          <description>A secondary objective is to compare the cellular immune response for Als3-specific production of IL-17A from PBMCs between the 2 dose levels, routes of administration, and effects of alum adjuvant, at selected time points up to 90 days post-vaccination. The IL-17A cellular immune responses will be evaluated by ELISpot using approximately 200,000 PBMCs per well. A positive response was defined as a sample with greater than 20 spot forming units per 10^6 PBMCs.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90/Exit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NDV-3 Vaccine With Alum</title>
          <description>NDV-3 (300 ug Als3) vaccine with alum administered IM: One dose administered IM</description>
        </group>
        <group group_id="E2">
          <title>NDV-3 Vaccine Without Alum</title>
          <description>NDV-3 (300 ug Als3) vaccine without alum administered IM: One dose administered IM</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo administered ID: One dose saline placebo administered ID</description>
        </group>
        <group group_id="E4">
          <title>NDV-3 Vaccine ID</title>
          <description>NDV-3 (30 ug Als3) vaccine without alum administered ID: One dose administered ID</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="41"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John P. Hennessey, Jr.</name_or_title>
      <organization>NovaDigm Therapeutics, Inc.</organization>
      <phone>12676405189</phone>
      <email>john_hennessey@novadigm.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

